Aviptadil is a 28-amino acid neurotransmitter and a vasoactive intestinal polypeptide (VIP) analog. It has an effective vasodilator effect, can induce pulmonary vasodilation, and inhibit vascular smooth muscle cell proliferation and platelet aggregation[1, 2]. Aviptadil can be used in the study of pulmonary fibrosis, pulmonary hypertension, and respiratory failure caused by SARS-CoV-2[3].
In vivo, Aviptadil (500μg/kg) was intraperitoneally injected into rats with pulmonary hypertension (PHT) for 3 weeks, completely preventing and significantly reversing monocrotaline (MCT)-induced pulmonary hypertension PAH, and had a synergistic effect with bosentan[4]. Aviptadil (150μg/kg/day) was intraperitoneally injected into rats with pulmonary hypertension for 4 weeks, eliminating bronchial hyperresponsiveness (BHR) and having bronchodilating properties[5]. Aviptadil (3μg/kg) was intravenously injected into rats with lung transplantation model and improved the rat lung transplantation reperfusion injury[6].
References:
[1] Hu J, Xu Q, McTiernan C, et al. Novel targets of drug treatment for pulmonary hypertension[J]. American Journal of Cardiovascular Drugs, 2015, 15: 225-234.
[2] O'Callaghan D S, Jaïs X, Montani D, et al. A Look to the Future: Potential Therapeutic Options for Pulmonary Arterial Hypertension[J]. The Annals of Respiratory Medicine, 2009, 1(1): 1.
[3] Chakraborty D, Choudhury S, Lahiry S. Aviptadil-class effect of a synthetic vasoactive intestinal peptide as a treatment option in COVID-19 patients with severe respiratory failure[J]. Indian Journal of Respiratory Care, 2022, 11(1): 5-5.
[4] Hamidi S A, Lin R Z, Szema A M, et al. VIP and endothelin receptor antagonist: an effective combination against experimental pulmonary arterial hypertension[J]. Respiratory research, 2011, 12: 1-7.
[5] Habre W, Albu G, Janosi T Z, et al. Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension[J]. Respiratory research, 2011, 12: 1-8.
[6] Nagahiro I, Yano M, Boasquevisque C H, et al. Vasoactive intestinal peptide ameliorates reperfusion injury in rat lung transplantation[J]. The Journal of Heart and Lung Transplantation: the Official Publication of the International Society for Heart Transplantation, 1998, 17(6): 617-621.
Aviptadil是一种具有28个氨基酸的神经递质，是一种血管活性肠多肽（VIP）类似物，具有有效的血管舒张作用，能够诱导肺血管扩张，抑制血管平滑肌细胞增殖、血小板聚集[1, 2]。Aviptadil能够用于肺纤维化、肺动脉高压、SARS-CoV-2引起呼吸衰竭等研究[3]。
在体内，Aviptadil（500μg/kg）通过腹腔注射治疗肺动脉高压（PHT）大鼠3周，完全预防并显著逆转了野百合碱（MCT）诱发的肺动脉高压PAH，并且和波生坦（Bosentan）具有协同作用[4]。Aviptadil（150μg/kg/day）通过腹腔注射治疗肺动脉高压大鼠4周，消除了支气管高反应性（BHR），具有支气管扩张的特性[5]。Aviptadil（3μg/kg）通过静脉注射治疗肺移植模型大鼠，改善了大鼠的肺移植再灌注损伤[6]。